Fiduciary Group LLC Has $1.74 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

Fiduciary Group LLC reduced its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 16.4% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 72,495 shares of the company's stock after selling 14,173 shares during the quarter. Fiduciary Group LLC's holdings in Kenvue were worth $1,738,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. LaFleur & Godfrey LLC grew its position in Kenvue by 29.8% during the fourth quarter. LaFleur & Godfrey LLC now owns 81,300 shares of the company's stock worth $1,736,000 after buying an additional 18,650 shares during the period. Proficio Capital Partners LLC acquired a new stake in shares of Kenvue in the 4th quarter worth approximately $1,643,000. Versor Investments LP purchased a new position in Kenvue in the 4th quarter valued at approximately $333,000. QRG Capital Management Inc. acquired a new position in Kenvue during the fourth quarter worth $218,000. Finally, SVB Wealth LLC purchased a new stake in Kenvue during the fourth quarter worth $478,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Redburn Atlantic assumed coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective for the company. Barclays upped their price objective on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. UBS Group boosted their target price on shares of Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Friday, May 9th. Citigroup reaffirmed a "neutral" rating on shares of Kenvue in a research note on Friday, June 13th. Finally, Canaccord Genuity Group boosted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $25.33.

Kenvue Stock Down 0.4%

NYSE:KVUE traded down $0.08 during trading hours on Wednesday, hitting $20.89. 18,186,686 shares of the stock traded hands, compared to its average volume of 16,119,267. The firm has a market cap of $40.08 billion, a price-to-earnings ratio of 37.98, a PEG ratio of 3.25 and a beta of 0.84. The firm has a 50 day moving average price of $22.69 and a 200 day moving average price of $22.33. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.63. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to analysts' expectations of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. Kenvue's revenue was down 3.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.28 EPS. Equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.93%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is currently 149.09%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.